The BioLineRx management team brings together seasoned executives with decades of experience in medicine, drug development, clinical studies, and financial and corporate development. Our management team is supported by a staff built of drug development professionals with experience in preclinical investigation, manufacturing and clinical testing, and physician-project managers with deep domain-specific expertise.

MORRIS C. LASTER, MD
CEO
Dr. Laster is a healthcare entrepreneur with over 14 years of experience in the biopharmaceutical industry. He previously founded four publicly traded companies including Keryx (simultaneous listing on NASDAQ: KERX; and AIM: KRX)), XTL (LSE: XTL) and Neose Technologies (NASDAQ: NTEC). During his time at Keryx, Dr. Laster was instrumental in changing FDA policy by securing a Subpart H accelerated approval strategy for diabetic nephropathy. Dr. Laster received his MD from Downstate Medical Center in New York and performed post graduate work in surgery at Case Western Reserve University Hospital in Ohio.



YURI SHOSHAN
Chief Financial Officer
Mr. Shoshan brings to BioLineRx over 10 years in strategy, finance, and alliance management experience. Prior to joining BioLineRx, Mr. Shoshan was a Principal at Pitango Venture Capital, focused on investments in the communications and software industries. At Pitango Mr. Shoshan led initial and follow-on financings and served as a board member for a number of Pitango portfolio companies. Mr. Shoshan began his career at McKinsey and Company where he advised Global 1000 clients in the US, Europe and Israel on strategic, organizational and operational issues, including large scale mergers and acquisitions. Mr. Shoshan holds an MBA in General Management from the Harvard Business School and a Bachelors Degree in Economics and Mathematics from Columbia University.




MOSHE PHILLIP, MD
Vice President of Medical Affairs and Senior Clinical Advisor
Professor Phillip is the Director of the Institute for Endocrinology and Diabetes, Israel National Center for Childhood Diabetes and served as the Vice Dean and Head of School for Continuing Medical Education of the Sackler School of Medical Education at Tel Aviv University. Professor Phillip manages the Institute’s Clinical Research Center (CRC), with in house research coordinators, statisticians, nurses and physicians.  Professor Phillip is the senior PI of numerous clinical studies including Growth hormone (norditropin), Lantus (Sanofi Aventis), Detemir (Novo Nordisk), Candersartan Cilexetil (Astra Zeneca), and Medtronic’s patented insulin pump and glucose sensors. Professor Phillip's expertise and experience in both bench and clinical research includes clinical studies from Phase II to post marketing. His bench research is focused mainly on finding ways to prevent diabetic complications and understanding the interaction between hormones and the epiphyseal growth plate, while his clinical research focuses on diabetes and growth, including studies in immunomodulation and prevention of diabetes mellitus. Professor Phillip is an Associate Editor and on the editorial board of 3 medical journals and a member of the Pediatric and Diabetic National Councils of Health.



KINNERET SAVITSKY, PhD
General Manager, BioLine Innovations Jerusalem
Dr. Savitsky leads BioLineRx's pre-clinical drug development efforts through BioLine Innovations Jerusalem. Dr. Savitsky was formerly the Vice President, Biology, Research and Development at Compugen (NASDAQ: CGEN), a leading biotechnology company. She joined Compugen in 1997 as a senior scientist in Compugen's newly founded laboratory and led the company's shift from computational genomics to development of diagnostics and therapeutics. She was responsible for all of Compugen's drug candidate identification and development, as well as experimental biology. At Compugen she managed a team of over 35 scientists and drug developers. Dr. Savitsky completed her PhD, with distinction, in the Department of Human Genetics at Tel Aviv University on the subject of identification of the gene responsible for a genetic disease. Dr. Savitsky also holds a BSc in Life Sciences from The Hebrew University of Jerusalem, and an MSc from the Department of Human Genetics at Tel Aviv University.




NIR GAMLIEL
Vice President of Business Development, BioLineRx USA, Inc.
Mr. Gamliel brings 15 years of experience in the healthcare industry to BioLineRx USA, Inc. Mr. Gamliel joined BioLineRx USA from the US office of BSP, Inc. (Biological Signal Processing, Inc.), a cardiology diagnostics company, where he was Vice President of Sales and Marketing. Previously, Mr. Gamliel served as Vice President of Sales at Compugen USA, Inc. (Nasdaq: CGEN). He also served as Sales & Marketing Manager for Europe at Voltaire Ltd. (Nasdaq: VOLT) and held a Franchise Manager position at Johnson & Johnson Medical Israel.